Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Jan 31;2013(1):CD004720.
doi: 10.1002/14651858.CD004720.pub3.

Screening for prostate cancer

Dragan Ilic  1 , Molly M Neuberger, Mia Djulbegovic, Philipp Dahm
Affiliations
Meta-Analysis

Screening for prostate cancer

Dragan Ilic et al. Cochrane Database Syst Rev. .

Abstract

Background: Any form of screening aims to reduce disease-specific and overall mortality, and to improve a person's future quality of life. Screening for prostate cancer has generated considerable debate within the medical and broader community, as demonstrated by the varying recommendations made by medical organizations and governed by national policies. To better inform individual patient decision-making and health policy decisions, we need to consider the entire body of data from randomised controlled trials (RCTs) on prostate cancer screening summarised in a systematic review. In 2006, our Cochrane review identified insufficient evidence to either support or refute the use of routine mass, selective, or opportunistic screening for prostate cancer. An update of the review in 2010 included three additional trials. Meta-analysis of the five studies included in the 2010 review concluded that screening did not significantly reduce prostate cancer-specific mortality. In the past two years, several updates to studies included in the 2010 review have been published thereby providing the rationale for this update of the 2010 systematic review.

Objectives: To determine whether screening for prostate cancer reduces prostate cancer-specific mortality or all-cause mortality and to assess its impact on quality of life and adverse events.

Search methods: An updated search of electronic databases (PROSTATE register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CANCERLIT, and the NHS EED) was performed, in addition to handsearching of specific journals and bibliographies, in an effort to identify both published and unpublished trials.

Selection criteria: All RCTs of screening versus no screening for prostate cancer were eligible for inclusion in this review.

Data collection and analysis: The original search (2006) identified 99 potentially relevant articles that were selected for full-text review. From these citations, two RCTs were identified as meeting the inclusion criteria. The search for the 2010 version of the review identified a further 106 potentially relevant articles, from which three new RCTs were included in the review. A total of 31 articles were retrieved for full-text examination based on the updated search in 2012. Updated data on three studies were included in this review. Data from the trials were independently extracted by two authors.

Main results: Five RCTs with a total of 341,342 participants were included in this review. All involved prostate-specific antigen (PSA) testing, with or without digital rectal examination (DRE), though the interval and threshold for further evaluation varied across trials. The age of participants ranged from 45 to 80 years and duration of follow-up from 7 to 20 years. Our meta-analysis of the five included studies indicated no statistically significant difference in prostate cancer-specific mortality between men randomised to the screening and control groups (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.86 to 1.17). The methodological quality of three of the studies was assessed as posing a high risk of bias. The European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial were assessed as posing a low risk of bias, but provided contradicting results. The ERSPC study reported a significant reduction in prostate cancer-specific mortality (RR 0.84, 95% CI 0.73 to 0.95), whilst the PLCO study concluded no significant benefit (RR 1.15, 95% CI 0.86 to 1.54). The ERSPC was the only study of the five included in this review that reported a significant reduction in prostate cancer-specific mortality, in a pre-specified subgroup of men aged 55 to 69 years of age. Sensitivity analysis for overall risk of bias indicated no significant difference in prostate cancer-specific mortality when referring to the meta analysis of only the ERSPC and PLCO trial data (RR 0.96, 95% CI 0.70 to 1.30). Subgroup analyses indicated that prostate cancer-specific mortality was not affected by the age at which participants were screened. Meta-analysis of four studies investigating all-cause mortality did not determine any significant differences between men randomised to screening or control (RR 1.00, 95% CI 0.96 to 1.03). A diagnosis of prostate cancer was significantly greater in men randomised to screening compared to those randomised to control (RR 1.30, 95% CI 1.02 to 1.65). Localised prostate cancer was more commonly diagnosed in men randomised to screening (RR 1.79, 95% CI 1.19 to 2.70), whilst the proportion of men diagnosed with advanced prostate cancer was significantly lower in the screening group compared to the men serving as controls (RR 0.80, 95% CI 0.73 to 0.87). Screening resulted in a range of harms that can be considered minor to major in severity and duration. Common minor harms from screening include bleeding, bruising and short-term anxiety. Common major harms include overdiagnosis and overtreatment, including infection, blood loss requiring transfusion, pneumonia, erectile dysfunction, and incontinence. Harms of screening included false-positive results for the PSA test and overdiagnosis (up to 50% in the ERSPC study). Adverse events associated with transrectal ultrasound (TRUS)-guided biopsies included infection, bleeding and pain. No deaths were attributed to any biopsy procedure. None of the studies provided detailed assessment of the effect of screening on quality of life or provided a comprehensive assessment of resource utilization associated with screening (although preliminary analyses were reported).

Authors' conclusions: Prostate cancer screening did not significantly decrease prostate cancer-specific mortality in a combined meta-analysis of five RCTs. Only one study (ERSPC) reported a 21% significant reduction of prostate cancer-specific mortality in a pre-specified subgroup of men aged 55 to 69 years. Pooled data currently demonstrates no significant reduction in prostate cancer-specific and overall mortality. Harms associated with PSA-based screening and subsequent diagnostic evaluations are frequent, and moderate in severity. Overdiagnosis and overtreatment are common and are associated with treatment-related harms. Men should be informed of this and the demonstrated adverse effects when they are deciding whether or not to undertake screening for prostate cancer. Any reduction in prostate cancer-specific mortality may take up to 10 years to accrue; therefore, men who have a life expectancy less than 10 to 15 years should be informed that screening for prostate cancer is unlikely to be beneficial. No studies examined the independent role of screening by DRE.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
2
2
Forest plot of comparison: 1 Screening versus control, outcome: 1.3 Prostate cancer‐specific mortality (subgroup analysis age)
3
3
Forest plot of comparison: 1 Screening versus control, outcome: 1.3 Prostate cancer‐specific mortality (sensitivity analysis overall risk of bias).
4
4
Forest plot of comparison: 1 Screening versus control, outcome: 1.5 All‐cause mortality (subgroup analysis age).
5
5
Forest plot of comparison: 1 Screening versus control, outcome: 1.9 Prostate cancer diagnosis (subgroup analysis age).
6
6
Forest plot of comparison: 1 Screening versus control, outcome: 1.11 Tumour stage (localised T1‐T2, N0, M0).
7
7
Forest plot of comparison: 1 Screening versus control, outcome: 1.12 Tumour stage (advanced T3‐4, N1, M1).
1.1
1.1. Analysis
Comparison 1 Screening versus control, Outcome 1 Prostate cancer‐specific mortality (subgroup analysis age).
1.2
1.2. Analysis
Comparison 1 Screening versus control, Outcome 2 Prostate cancer‐specific mortality (subgroup analysis age, including ERSPC 'core' age group).
1.3
1.3. Analysis
Comparison 1 Screening versus control, Outcome 3 Prostate cancer‐specific mortality (sensitivity analysis overall risk of bias).
1.4
1.4. Analysis
Comparison 1 Screening versus control, Outcome 4 Prostate cancer‐specific mortality (sensitivity analysis overall risk of bias, including ERSPC 'core' age group).
1.5
1.5. Analysis
Comparison 1 Screening versus control, Outcome 5 All‐cause mortality (subgroup analysis age).
1.6
1.6. Analysis
Comparison 1 Screening versus control, Outcome 6 All‐cause mortality (subgroup analysis age, including ERSPC 'core' age group).
1.7
1.7. Analysis
Comparison 1 Screening versus control, Outcome 7 All‐cause mortality (sensitivity analysis overall risk of bias).
1.8
1.8. Analysis
Comparison 1 Screening versus control, Outcome 8 All‐cause mortality (sensitivity analysis overall risk of bias, including ERSPC 'core' age group).
1.9
1.9. Analysis
Comparison 1 Screening versus control, Outcome 9 Prostate cancer diagnosis (subgroup analysis age).
1.10
1.10. Analysis
Comparison 1 Screening versus control, Outcome 10 Prostate cancer diagnosis (subgroup analysis age, including ERSPC 'core' age group).
1.11
1.11. Analysis
Comparison 1 Screening versus control, Outcome 11 Tumour stage (localised T1‐T2, N0, M0).
1.12
1.12. Analysis
Comparison 1 Screening versus control, Outcome 12 Tumour stage (advanced T3‐4, N1, M1).
See this image and copyright information in PMC

Update of

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

ERSPC {published and unpublished data}
    1. Carlsson SV, Holmberg E, Moss SM, Roobol MJ, Schröder FH, Tammela TLJ, et al. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU International 2011;107(12):1912‐7. - PubMed
    1. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population‐based prostate‐cancer screening trial. Lancet Oncology 2010;11(8):725‐32. - PMC - PubMed
    1. Kilpeläinen TP, Auvinen A, Määttänen L, Kujala P, Ruutu M, Stenman U‐H, et al. Results of the three rounds of the Finnish Prostate Cancer Screening Trial ‐ the incidence of advanced cancer is decreased by screening. International Journal of Cancer 2010;127(7):1699‐705. - PubMed
    1. Kilpeläinen TP, Tammela TLJ, Roobol M, Hugosson J, Ciatto S, Nelen V, et al. False‐positive screening results in the European randomized study of screening for prostate cancer. European Journal of Cancer 2011;47(18):2698‐705. - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Prostate‐cancer mortality at 11 years of follow‐up. The New England Journal of Medicine 2012;366(11):981‐90. - PMC - PubMed
Norrkoping {published and unpublished data}
    1. Carlsson P, Pedersen KV, Varenhorst E. Costs and benefits of early detection of prostatic cancer. Health Policy 1990;16:241‐53. - PubMed
    1. Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow‐up of a randomised controlled trial in Sweden. European Urology 2004;46:717‐24. - PubMed
    1. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow‐up. BMJ 2011;342:d1539. - PMC - PubMed
    1. Varenhorst E, Carlsson P, Capik E, Lofman O, Pedersen K. Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Acta Oncologica 1992;31(8):815‐21. - PubMed
PLCO {published and unpublished data}
    1. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate‐cancer screening trial. The New England Journal of Medicine 2009;360(13):1310‐9. - PMC - PubMed
    1. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow‐up. Journal of the National Cancer Institute 2012;104(2):125‐32. - PMC - PubMed
    1. Crawford ED, Grubb R 3rd, Black A, Andriole GL Jr, Chen M‐H, Izmirlian G, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. Journal of Clinical Oncology 2011;29(4):355‐61. - PMC - PubMed
    1. Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu J‐L, Baker SG, et al. Cumulative incidence of false‐positive results in repeated, multimodal cancer screening. Annals of Family Medicine 2009;7(3):212‐22. - PMC - PubMed
    1. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials 2000;21 (6 Suppl):273S‐309S. - PubMed
Quebec {published data only (unpublished sought but not used)}
    1. Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G, et al. 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004;59(3):311‐8. - PubMed
    1. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu R, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38(2):83‐91. - PubMed
    1. Labrie F, Cusan L, Gomez JL, Levesque J, Candas B. Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. The Aging Male 1999;2(1):33‐43.
Stockholm {published data only}
    1. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. 15‐Year follow up of a population based prostate cancer screening study. The Journal of Urology 2009;181:1615‐21. - PubMed
    1. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. Dihydrotestosterone levels and survival in screening‐detected prostate cancer: A 15‐yr follow‐up study. European Urology 2007;53:106‐11. - PubMed

References to studies excluded from this review

Agalliu 2007 {published data only}
    1. Agalliu I, Weiss NS, Lin DW, Stanford JL. Prostate cancer mortality in relation to screening by prostate‐specific antigen testing and digital rectal examination: a population‐based study in middle‐aged men. Cancer Causes & Control 2007;18(9):931‐7. - PubMed
Ahmed 2008 {published data only}
    1. Ahmed FS, Borrell LN, Spencer BA. Health risk behaviors and prostate specific antigen awareness among men in California. The Journal of Urology 2008;180(2):658‐62. - PMC - PubMed
Anonymous 2000 {published data only}
    1. Anonymous. From the Centers for Disease Control and Prevention. Screening with the prostate‐specific antigen test ‐ Texas, 1997. JAMA 2000;284(18):2313‐4. - PubMed
Anonymous 2008 {published data only}
    1. Anonymous. Prostate cancer screening. Medical Letter on Drugs & Therapeutics 2008;50:85‐6. - PubMed
Aus 2001 {published data only}
    1. Aus G, Bergdahl S, Hugosson J, Lodding P, Pihl CG, Pileblad E. Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50 ‐ 66 years. Implications for sampling order. European Urology 2001;39(6):655‐60. - PubMed
Aus 2004 {published data only}
    1. Aus G, Becker C, Franzen S, Lilja H, Lodding P, Hugosson J. Cumulative prostate cancer risk assessment with the aid of the free‐to‐total prostate specific antigen ratio. European Urology 2004;45(2):160‐5. - PubMed
Aus 2005 {published data only}
    1. Aus G, Damber J‐E, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate‐specific antigen level: results of a prospective, randomized, population‐based study. Archives of Internal Medicine 2005;165(16):1857‐61. - PMC - PubMed
Aus 2007 {published data only}
    1. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer‐‐results from a prospective, population‐based randomized controlled trial. European Urology 2007;51(3):659‐64. - PubMed
Auvinen 1996 {published data only}
    1. Auvinen A, Tammela T, Stenman U‐H, Uusi‐Erkkilä I, Leinonen J, Schröder FH, et al. Screening for prostate cancer using serum prostate‐specific antigen: a randomised, population‐based pilot study in Finland. British Journal of Cancer 1996;74(4):568‐72. - PMC - PubMed
Auvinen 2009 {published data only}
    1. Auvinen A, Raitanen J, Moss S, Koning HJ, Hugosson J, Tammela T, et al. Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands. Cancer Epidemiology, Biomarkers & Prevention 2009;18(7):2000‐5. - PubMed
Bangma 1995a {published data only}
    1. Bangma CH, Grobbee DE, Schröder FH. Volume adjustment for intermediate prostate‐specific antigen values in a screening population. European Journal of Cancer 1995;31A(1):12‐4. - PubMed
Bangma 1995b {published data only}
    1. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate‐specific analysis ratio, age‐specific reference ranges, and PSA density. Urology 1995;46(6):779‐84. - PubMed
Bangma 1995c {published data only}
    1. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Urology 1995;46(6):773‐8. - PubMed
Bangma 1997 {published data only}
    1. Bangma CH, Rietbergen JB, Schröder FH. Prostate‐specific antigen as a screening test. The Netherlands experience. Urologic Clinics of North America 1997;24(2):307‐14. - PubMed
Beemsterboer 1999 {published data only}
    1. Beemsterboer PMM, Kranse R, Koning HJ, Habbema JDF, Schröder FH. Changing role of 3 screening modalities in the European Randomized Study of Screening for Prostate Cancer (Rotterdam). International Journal of Cancer 1999;84(4):437‐41. - PubMed
Beemsterboer 2000 {published data only}
    1. Beemsterboer PMM, Koning HJ, Kranse R, Trienekens PH, Maas PJ, Schröder FH. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European Randomized Study of Screening for Prostate Cancer, Rotterdam. The Journal of Urology 2000;164(4):1216‐20. - PubMed
Bergstralh 2007 {published data only}
    1. Bergstralh EJ, Roberts RO, Farmer SA, Slezak JM, Lieber MM, Jacobsen SJ. Population‐based case‐control study of PSA and DRE screening on prostate cancer mortality. Urology 2007;70(5):936‐41. - PMC - PubMed
Boevee 2010 {published data only}
    1. Boevee SJ, Venderbos LDF, Tammela TLJ, Nelen V, Ciatto S, Kwiatkowski M, et al. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. European Journal of Cancer 2010;46(17):3082‐9. - PubMed
Borre 2007 {published data only}
    1. Borre M, Iversen P. Screening for prostate cancer‐what does the evidence show?. Ugeskrift for Laeger 2007;169:1887‐8. - PubMed
Bul 2011 {published data only}
    1. Bul M, Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ. Prostate cancer incidence and disease‐specific survival of men with initial prostate‐specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. European Urology 2011;59(4):498‐505. - PubMed
Bunker 2007 {published data only}
    1. Bunker CH, McDonald AC, Evans RW, Rosa N, Boumosleh JM, Patrick AL. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutrition and Cancer 2007;57:130‐7. - PubMed
Candas 2000 {published data only}
    1. Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Levesque J, et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 2000;45(1):19‐35. - PubMed
Carlsson 2007 {published data only}
    1. Carlsson S, Aus G, Wessman C, Hugosson J. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) ‐ Results from a prospective, population‐based, randomised study. European Journal of Cancer 2007;43:2109‐16. - PubMed
Carlsson 2011 {published data only}
    1. Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Stranne J, et al. The excess burden of side‐effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population‐based prostate cancer screening trial. European Journal of Cancer 2011;47(4):545‐53. - PubMed
Carriere 2007 {published data only}
    1. Carriere P, Baade P, Newman B, Aitken J, Janda M. Cancer screening in Queensland men. Medical Journal of Australia 2007;186:404‐7. - PubMed
Chavarro 2008 {published data only}
    1. Chavarro JE, Stampfer MJ, Campos H, Kurth T, Willett WC, Ma J. A prospective study of trans‐fatty acid levels in blood and risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 2008;17:95‐101. - PubMed
Ciatto 1993 {published data only}
    1. Ciatto S, Bonardi R, Mazzotta A, Lombardi C, Zappa M. Clinico‐echographic screening in the early diagnosis of prostatic carcinoma. Preliminary results of a feasibility study of a randomized trial. La Radiologia Medica 1993;85(4):430‐3. - PubMed
Ciatto 1994 {published data only}
    1. Ciatto S, Bonardi R, Mazzotta A, Lombardi C, Santoni R, Cardini S, et al. Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen. La Radiologia Medica 1994;88(4):453‐7. - PubMed
Ciatto 2002 {published data only}
    1. Ciatto S, Bonardi R, Lombardi C, Zappa M, Gervasi G, Cappelli G. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds. International Journal of Biological Markers 2002;17(2):79‐83. - PubMed
Ciatto 2003b {published data only}
    1. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU International 2003;2:97‐100. - PubMed
Ciatto 2008 {published data only}
    1. Ciatto S, Rubeca T, Martinelli F, Pontenani G, Lombardi C, Lollo S. PSA doubling time as a predictor of the outcome of random prostate biopsies prompted by isolated PSA elevation in subjects referred to an outpatient biopsy facility in a routine clinical scenario. International Journal of Biological Markers 2008;23:187‐91. - PubMed
Collin 2008 {published data only}
    1. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. Prostate‐cancer mortality in the USA and UK in 1975‐2004: an ecological study. Lancet Oncology 2008;9:445‐52. - PMC - PubMed
Concato 2009 {published data only}
    1. Concato J. What will the emperor say? Screening for prostate cancer as of 2008. Cancer Journal 2009;15:7‐12. - PubMed
Cusan 1994 {published data only}
    1. Cusan L. Prostate cancer screening with PSA, DRE and TRUS. Canadian Journal of Oncology 1994;1:63‐4. - PubMed
D'Amico 2007 {published data only}
    1. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate‐specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncology 2007;8:21‐5. - PubMed
de Koning 2002 {published data only}
    1. Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, et al. Large‐scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. International Journal of Cancer 2002;97(2):237‐44. - PubMed
Döbrőssy 2007 {published data only}
    1. Döbrőssy L, Kovács A, Budai A, Cornides A. Is the mass screening for prostate cancer justifiable? [Indokolt‐e a népegészségügyi prosztataszűrés?]. Orvosi Hetilap 2007;148(26):1213‐6. - PubMed
Draisma 2009 {published data only}
    1. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and over diagnosis in prostate‐specific antigen screening: importance of methods and context. Journal of the National Cancer Institute 2009;101:374‐83. - PMC - PubMed
Driscoll 2008 {published data only}
    1. Driscoll DL, Rupert DJ, Golin CE, McCormack LA, Sheridan SL, Welch BM, et al. Promoting prostate‐specific antigen informed decision‐making. Evaluating two community‐level interventions. American Journal of Preventive Medicine 2008;35:87‐94. - PubMed
Ellison 2008 {published data only}
    1. Ellison GL, Weinrich SP, Lou M, Xu H, Powell IJ, Baquet CR. A randomized trial comparing web‐based decision aids on prostate cancer knowledge for African‐American men. Journal of the National Medical Association 2008;100:1139‐45. - PMC - PubMed
Essink‐Bot 1998 {published data only}
    1. Essink‐Bot M‐L, Koning HJ, Nijs HGT, Kirkels WJ, Maas PJ, Schröder FH. Short‐term effects of population‐based screening for prostate cancer on health‐related quality of life. Journal of the National Cancer Institute 1998;90(12):925‐31. - PubMed
Etzioni 2008 {published data only}
    1. Etzioni R. Statistical issues in the evaluation of screening and early detection modalities. Urologic Oncology 2008;26:308‐15. - PubMed
Fenton 2008 {published data only}
    1. Fenton JJ, Franks P, Reid RJ, Elmore JG, Baldwin LM. Continuity of care and cancer screening among health plan enrollees. Medical Care 2008;46:58‐62. - PubMed
Finne 2002 {published data only}
    1. Finne P, Auvinen A, Aro J, Juusela H, Maattanen L, Rannikko S, et al. Estimation of prostate cancer risk on the basis of total and free prostate‐specific antigen, prostate volume and digital rectal examination. European Urology 2002;41(6):619‐26. - PubMed
Finne 2010 {published data only}
    1. Finne P, Fallah M, Hakama M, Ciatto S, Hugosson J, Koning H, et al. Lead‐time in the European Randomised Study of Screening for Prostate Cancer. European Journal of Cancer 2010;46(17):3102‐8. - PubMed
Fitzpatrick 2009 {published data only}
    1. Fitzpatrick JM, Banu E, Oudard S. Prostate‐specific antigen kinetics in localized and advanced prostate cancer. BJU International 2009;103:578‐87. - PubMed
Fleshner 2007 {published data only}
    1. Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, et al. Delay in the progression of low‐risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemporary Clinical Trials 2007;28:763‐9. - PubMed
Fleshner 2009 {published data only}
    1. Fleshner NE, Lawrentschuk N. Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology 2009;73(Suppl 5A):S21‐7. - PubMed
Ford 2003 {published data only}
    1. Ford ME, Havstad SL, Tilley BC. Recruiting older African American men to a cancer screening trial (the AAMEN Project). Gerontologist 2003;43(1):27‐35. - PubMed
Ford 2008 {published data only}
    1. Ford ME, Havstad SL, Fields ME, Manigo B, McClary B, Lamerato L. Effects of baseline comorbidities on cancer screening trial adherence among older African American men. Cancer Epidemiology, Biomarkers & Prevention 2008;17:1234‐9. - PMC - PubMed
Frosch 2008 {published data only}
    1. Frosch DL, Bhatnagar V, Tally S, Hamori CJ, Kaplan RM. Internet patient decision support: a randomized controlled trial comparing alternative approaches for men considering prostate cancer screening. Archives of Internal Medicine 2008;168:363‐9. - PubMed
Gohagan 1994a {published data only}
    1. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. The Journal of Urology 1994;152(5 Pt 2):1905‐9. - PubMed
Gohagan 1994b {published data only}
    1. Gohagan JK, Kramer BS, Greenwald P. Screening for prostate cancer. American Journal of Preventive Medicine 1994;10(4):245‐6. - PubMed
Gohagan 1995 {published data only}
    1. Gohagan JK, Prorok PC, Kramer BS, Hayes RB, Cornett J. The Prostate, Lung, Colorectal, and Ovarian cancer screening trial of the National Cancer Institute. Cancer 1995;75(7 Suppl):1869‐73.
Gohagan 2000 {published data only}
    1. Gohagan JK, Prorok PC, Hayes RB, Kramer BS, for the PLCO Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Controlled Clinical Trials 2000;21(6 Suppl 1):251S‐72S. - PubMed
Gonzalgo 2007 {published data only}
    1. Gonzalgo ML, Carter HB. Update on PSA testing. Journal of the National Comprehensive Cancer Network 2007;5:737‐42. - PubMed
Gosselaar 2008 {published data only}
    1. Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schröder FH. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 2008;68:985‐93. - PubMed
Gosselaar 2008b {published data only}
    1. Gosselaar C, Roobol MJ, Roemeling S, Wolters T, Leenders GJ, Schröder FH. The value of an additional hypoechoic lesion‐directed biopsy core for detecting prostate cancer. BJU International 2008;101:685‐90. - PubMed
Grosclaude 2008 {published data only}
    1. Grosclaude P. Prostate cancer: an update on screening. Bulletin de l'Acadmie Nationale de Medicine 2008;192:1013‐8. - PubMed
Grubb 2008 {published data only}
    1. Grubb RL 3rd, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU International 2008;102:1524‐30. - PubMed
Grubb 2009 {published data only}
    1. Grubb RL, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, et al. Serum prostate‐specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiology, Biomarkers & Prevention 2009;18:748‐51. - PubMed
Gustafsson 1992 {published data only}
    1. Gustafsson O, Norming U, Almgard LE, Fredriksson A, Gustavsson G, Harvig B, et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. The Journal of Urology 1992;148(6):1827‐31. - PubMed
Gustafsson 1995 {published data only}
    1. Gustafsson O, Carlsson P, Norming U, Nyman CR, Svensson H. Cost‐effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men. Prostate 1995;26(6):299‐309. - PubMed
Gustafsson 1998 {published data only}
    1. Gustafsson O, Mansour E, Norming U, Carlsson A, Tornblom M, Nyman CR. Prostate‐specific antigen (PSA), PSA density and age‐adjusted PSA reference values in screening for prostate cancer ‐ a study of a randomly selected population of 2,400 men. Scandinavian Journal of Urology and Nephrology 1998;32(6):373‐7. - PubMed
Heijnsdijk 2009 {published data only}
    1. Heijnsdijk E, Kinderen A, Wever E, Draisma G, Roobol M, Koning H. Overdetection, overtreatment and costs in prostate‐specific antigen screening for prostate cancer. British Journal of Cancer 2009;101:1833‐8. - PMC - PubMed
Hoedemaeker 1999 {published data only}
    1. Hoedemaeker RF, Kranse R, Rietbergen JB, Kruger AE, Schroder FH, Kwast TH. Evaluation of prostate needle biopsies in a population‐based screening study: the impact of borderline lesions. Cancer 1999;85(1):145‐52. - PubMed
Hoedemaeker 2001 {published data only}
    1. Hoedemaeker RF, Kwast TH, Boer R, Koning HJ, Roobol M, Vis AN, et al. Pathologic features of prostate cancer found at population‐based screening with a four‐year interval. Journal of the National Cancer Institute 2001;93(15):1153‐8. - PubMed
Horinaga 2007 {published data only}
    1. Horinaga M, Kitamura K, Saito S, Ukimura O, Nakanoma T, Okihara K, et al. Prostate cancer screening with prostate‐specific antigen in hemodialysis patients. Urologia Internationalis 2007;78:334‐7. - PubMed
Hosseini 2007 {published data only}
    1. Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR. Population‐based screening for prostate cancer by measuring total serum prostate‐specific antigen in Iran. International Journal of Urology 2007;14:406‐11. - PubMed
Imamura 2008 {published data only}
    1. Imamura T, Yasunaga H. Economic evaluation of prostate cancer screening with prostate‐specific antigen. International Journal of Urology 2008;15:285‐8. - PubMed
Janes 2008 {published data only}
    1. Janes H, Pepe MS. Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. American Journal of Epidemiology 2008;168:89‐97. - PubMed
Jegu 2009 {published data only}
    1. Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, et al. Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Herault [État des lieux et facteurs de participation à l’étude européenne ERSPC de dépistage randomisé du cancer de la prostate par dosage sérique de l’antigène prostatique spécifique : départements français du Tarn et de l’Hérault]. Progrès en Urologie 2009;19(7):487‐98. - PubMed
Johansen 2008 {published data only}
    1. Johansen TE, Berg C. Hormone treatment of prostate cancer in Norway [Hormonbehandling av prostatakreft i Norge]. Tidsskrift for Den Norske Laegeforening 2008;128(22):2558‐62. - PubMed
Kawamura 2008 {published data only}
    1. Kawamura K, Suzuki H, Kamiya N, Imamoto T, Yano M, Miura J, et al. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. International Journal of Urology 2008;15:598‐603. - PubMed
Kerfoot 2008 {published data only}
    1. Kerfoot BP. Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. The Journal of Urology 2008;179:2356‐7. - PubMed
Kerfoot 2009 {published data only}
    1. Kerfoot BP, Brotschi E. Online spaced education to teach urology to medical students: a multi‐institutional randomized trial. American Journal of Surgery 2009;197:89‐95. - PubMed
Kerkhof 2010 {published data only}
    1. Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH, et al. Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam). International Journal of Cancer 2010;127(11):2639‐44. - PubMed
Kerns 2008 {published data only}
    1. Kerns JW, Krist AH, Woolf SH, Flores SK, Johnson RE. Patient perceptions of how physicians communicate during prostate cancer screening discussions: a comparison of residents and faculty. Family Medicine 2008;40:181‐7. - PubMed
Khatami 2007 {published data only}
    1. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. International Journal of Cancer 2007;120:170‐4. - PubMed
Khatami 2009 {published data only}
    1. Khatami A, Hugosson J, Wang W, Damber JE. Ki‐67 in screen‐detected, low‐grade, low‐stage prostate cancer, relation to prostate‐specific antigen doubling time, Gleason score and prostate‐specific antigen relapse after radical prostatectomy. Scandinavian Journal of Urology and Nephrology 2009;43(1):12‐8. - PubMed
Kiemeny 2008 {published data only}
    1. Kiemeney LA, Broeders MJ, Pelger M, Kil PJ, Schröder FH, Witjes JA, et al. Screening for prostate cancer in Dutch hereditary prostate cancer families. International Journal of Cancer 2008;122:871‐6. - PubMed
Kilpeläinen 2010 {published data only}
    1. Kilpeläinen TP, Tammela TLJ, Määttänen L, Kujala P, Stenman U‐H, Ala‐Opas M, et al. False‐positive screening results in the Finnish prostate cancer screening trial. British Journal of Cancer 2010;102(3):469‐74. - PMC - PubMed
Klotz 2008 {published data only}
    1. Klotz L. Active surveillance for prostate cancer: trials and tribulations. World Journal of Urology 2008;26:437‐42. - PubMed
Kramer 2009 {published data only}
    1. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, et al. Use of 5alpha‐reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. The Journal of Urology 2009;181:1642‐57. - PubMed
Kramer 2009b {published data only}
    1. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, et al. Use of 5‐alpha‐reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. Journal of Clinical Oncology 2009;27:1502‐16. - PMC - PubMed
Kripalani 2007 {published data only}
    1. Kripalani S, Sharma J, Justice E, Justice J, Spiker C, Laufman LE, et al. Low‐literacy interventions to promote discussion of prostate cancer: a randomized controlled trial. American Journal of Preventive Medicine 2007;33:83‐90. - PMC - PubMed
Krist 2007 {published data only}
    1. Krist AH, Woolf SH, Johnson RE. How physicians approach prostate cancer screening before and after losing a lawsuit. Annals of Family Medicine 2007;5:120‐5. - PMC - PubMed
Labrie 1992 {published data only}
    1. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre‐screening test for prostate cancer. The Journal of Urology 1992;147(3 Pt 2):846‐51. - PubMed
Labrie 1996 {published data only}
    1. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate‐specific antigen. Urology 1996;47(2):212‐7. - PubMed
Laurila 2010 {published data only}
    1. Laurila M, Kwast T, Bubendorf L, Lollo S, Pihl C‐G, Ciatto S, et al. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer. European Journal of Cancer 2010;46(17):3068‐72. - PubMed
Leitzmann 2008 {published data only}
    1. Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, et al. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes & Control 2008;19:1267‐76. - PMC - PubMed
Leoni 2008 {published data only}
    1. Leoni M, Falcini F, Ravaioli A, Foca F, Andalo G, Benini F, et al. Estimating standard performance measures of opportunistic screening for prostate cancer [Stima di misure di processo standard dell’attività spontanea di screening per il cancro prostatico]. Epidemiologia e Prevenzione 2008;32(6):285‐93. - PubMed
Lim 2008 {published data only}
    1. Lim LS, Sherin K, ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men: ACPM position statement on preventive practice. American Journal of Preventive Medicine 2008;34(2):164‐70. - PubMed
Lin 2006 {published data only}
    1. Lin AM, Small EJ. Prostate cancer update: 2006. Current Opinion in Oncology 2006;19:229‐33. - PubMed
Lin 2008 {published data only}
    1. Lin K, Lipsitz R, Miller T, Janakiraman S, U.S. Preventive Services Task Force. Benefits and harms of prostate‐specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2008;149:192‐9. - PubMed
Lobel 2007 {published data only}
    1. Lobel B. Does localized prostate cancer exist?. Recent Results in Cancer Research 2007;175:101‐7. - PubMed
Lodding 1998 {published data only}
    1. Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl CG, et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. Prostate specific antigen. The Journal of Urology 1998;159(3):899‐903. - PubMed
Lucia 2008 {published data only}
    1. Lucia MS, Darke AK, Goodman PJ, Rosa FG, Parnes HL, Ford LG, et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prevention Research 2008;1:167‐73. - PMC - PubMed
Lujan 2004 {published data only}
    1. Lujan M, Paez A, Miravalles E, Fernandez I, Llanes L, Berenguer A. Prostate cancer detection is also relevant in low prostate specific antigen ranges. European Urology 2004;45(2):155‐9. - PubMed
Määttänen 1999 {published data only}
    1. Määttänen L, Auvinen A, Stenman U‐H, Rannikko S, Tammela T, Aro J, et al. European randomized study of prostate cancer screening: first‐year results of the Finnish trial. British Journal of Cancer 1999;79(7‐8):1210‐4. - PMC - PubMed
Määttänen 2001 {published data only}
    1. Määttänen L, Auvinen A, Stenman U‐H, Tammela T, Rannikko S, Aro J, et al. Three‐year results of the Finnish prostate cancer screening trial. Journal of the National Cancer Institute 2001;93(7):552‐3. - PubMed
Määttänen 2007 {published data only}
    1. Määttänen L, Hakama M, Tammela TLJ, Ruutu M, Ala‐Opas M, Juusela H, et al. Specificity of serum prostate‐specific antigen determination in the Finnish prostate cancer screening trial. British Journal of Cancer 2007;96:56‐60. - PMC - PubMed
Makinen 2001 {published data only}
    1. Makinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, et al. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. The Journal of Urology 2001;166(4):1339‐42. - PubMed
Makinen 2002 {published data only}
    1. Makinen T, Tammela TL, Stenman UH, Maattanen L, Rannikko S, Aro J, et al. Family history and prostate cancer screening with prostate‐specific antigen. Journal of Clinical Oncology 2002;20(11):2658‐63. - PubMed
Makinen 2004 {published data only}
    1. Makinen T, Tammela T, Stenman U, Maattanen L, Aro J, Juusela H, et al. Second round results of the Finnish population based prostate cancer screening trial. Clinical Cancer Research 2004;10:2231‐6. - PubMed
Mao 2007 {published data only}
    1. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, et al. Employing the treatment‐free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 2007;67:1677‐85. - PubMed
Marcella 2008 {published data only}
    1. Marcella SW, Rhoads GG, Carson JL, Merlino F, Wilcox H. Prostate‐specific antigen screening and mortality from prostate cancer. Journal of General Internal Medicine 2008;23:248‐53. - PMC - PubMed
Meeks 2008 {published data only}
    1. Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, Catalona WJ. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer. The Journal of Urology 2008;179:1340‐3. - PubMed
Mitterberger 2007 {published data only}
    1. Mitterberger M, Horninger W, Pelzer A, Strasser H, Bartsch G, Moser P, et al. A prospective randomized trial comparing contrast‐enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection. Prostate 2007;67:1537‐42. - PubMed
Nanri 2007 {published data only}
    1. Nanri M, Nanri K, Fujiyama C, Tokuda Y, Nakamura K, Uozumi J. Prostate‐specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer. International Journal of Urology 2007;14:505‐9. - PubMed
Nelen 2010 {published data only}
    1. Nelen V, Thys G, Hermans A, D'Hooge K, Dourcy‐Belle‐Rose B, Coebergh J‐W, et al. Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6 year screening interval. European Journal of Cancer 2010;46(17):3090‐4. - PubMed
Norming 1991 {published data only}
    1. Norming U, Gustafsson O, Nyman CR, Almgard L, Fredriksson A, Gustafsson G, et al. Digital rectal examination versus transrectal ultrasound in detection of prostate cancer. Preliminary results from a study of a randomly selected population. Acta Oncologica 1991;30(2):277‐9. - PubMed
Otto 2003 {published data only}
    1. Otto SJ, Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schröder FH, et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. International Journal of Cancer 2003;105(3):394‐9. - PubMed
Otto 2010 {published data only}
    1. Otto SJ, Moss SM, Määttänen L, Roobol M, Zappa M, Nelen V, et al. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. European Journal of Cancer 2010;46(17):3053‐60. - PubMed
Pedersen 1990 {published data only}
    1. Pedersen KV, Carlsson P, Varenhorst E, Lofman O, Berglund K. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 1990;300(6731):1041‐4. - PMC - PubMed
Pienta 2009 {published data only}
    1. Pienta KJ. Critical appraisal of prostate‐specific antigen in prostate cancer screening: 20 years later. Urology 2009;73(5 Suppl):S11‐20. - PubMed
Pinksy 2007 {published data only}
    1. Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, et al. Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial. BJU International 2007;99(4):775‐9. - PubMed
Pinsky 2010 {published data only}
    1. Pinsky P, Blacka A, Kramer B, Miller A, Prorok P, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clinical Trials 2010;7:303‐11. - PubMed
Postma 2004 {published data only}
    1. Postma R, Roobol M, Schröder FH, Kwast TH. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 2004;100(5):968‐75. - PubMed
Postma 2007 {published data only}
    1. Postma R, Schröder FH, Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) ‐ Section Rotterdam. A comparison of two rounds of screening. European Urology 2007;52:89‐97. - PubMed
Prorok 1994 {published data only}
    1. Prorok P. The National Cancer Institute Multi‐Screening Trial. Canadian Journal of Oncology 1994;1:98‐9. - PubMed
Raaijmakers 2004a {published data only}
    1. Raaijmakers R, Blijenberg BG, Finlay JA, Rittenhouse HG, Wildhagen MF, Roobol MJ, et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. The Journal of Urology 2004;171(6 Pt 1):2245‐9. - PubMed
Raaijmakers 2004b {published data only}
    1. Raaijmakers R, Wildhagen MF, Ito K, Paez A, Vries SH, Roobol MJ, et al. Prostate‐specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004;63(2):316‐20. - PubMed
Raaijmakers 2007 {published data only}
    1. Raaijmakers R, Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen‐detected men within the PSA range 4‐10 ng/ml. European Urology 2007;52:1358‐64. - PubMed
Rauscher 2008 {published data only}
    1. Rauscher GH, Johnson TP, Cho YI, Walk JA. Accuracy of self‐reported cancer‐screening histories: a meta‐analysis. Cancer Epdemiology, Biomarkers & Prevention 2008;17:748‐57. - PubMed
Recker 2001 {published data only}
    1. Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free‐to‐total ratio 20% or less: the Aarau experience. The Journal of Urology 2001;166(3):851‐5. - PubMed
Richard 2009 {published data only}
    1. Richard F. Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial [Dépistage du cancer de la prostate : les données du premier tour de dépistage de la population française participant à l’essai européen ERSPC]. Progrès en Urologie 2009;19(7):499‐500. - PubMed
Rietbergen 1997a {published data only}
    1. Rietbergen JBW, Kranse R, Kirkels WJ, Koning HJ, Schröder FH. Evaluation of prostate‐specific antigen, digital rectal examination and transrectal ultrasonography in population‐based screening for prostate cancer: improving the efficiency of early detection. British Journal of Urology 1997;79 Suppl 2:57‐63. - PubMed
Rietbergen 1997b {published data only}
    1. Rietbergen JB, Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound‐guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population‐based screening program. Urology 1997;49(6):875‐80. - PubMed
Rietbergen 1998a {published data only}
    1. Rietbergen JB, Kranse R, Hoedemaeker RF, Kruger AE, Bangma CH, Kirkels WJ, et al. Comparison of prostate‐specific antigen corrected for total prostate volume and transition zone volume in a population‐based screening study. Urology 1998;52(2):237‐46. - PubMed
Rietbergen 1998b {published data only}
    1. Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schröder FH. Repeat screening for prostate cancer after 1‐year followup in 984 biopsied men: clinical and pathological features of detected cancer. The Journal of Urology 1998;160(6 Pt 1):2121‐5. - PubMed
Rietbergen 1999 {published data only}
    1. Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schröder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. The Journal of Urology 1999;161(4):1192‐8. - PubMed
Roemeling 2007 {published data only}
    1. Roemeling S, Roobol MJ, Kattan MW, Kwast TH, Steyerberg EW, Schröder FH. Nomogram use for the prediction of indolent prostate cancer: impact on screen‐detected populations. Cancer 2007;110:2218‐21. - PubMed
Roemeling 2007b {published data only}
    1. Roemeling S, Roobol MJ, Otto SJ, Habbema DF, Gosselaar C, Lous JJ, et al. Feasibility study of adjustment for contamination and non‐compliance in a prostate cancer screening trial. Prostate 2007;67:1053‐60. - PubMed
Roemeling 2007c {published data only}
    1. Roemeling S, Roobol MJ, Vries SH, Wolters T, Gosselaar C, Leenders GJ, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. European Urology 2007;51:1244‐50. - PubMed
Romero 2008 {published data only}
    1. Romero FR, Romero AW, Brenny Filho T, Bark NM, Yamazaki DS, Oliveira FC. Patients' perceptions of pain and discomfort during digital rectal exam for prostate cancer screening. Archivos Españoles de Urología 2008;61(7):850‐4. - PubMed
Roobol 2004 {published data only}
    1. Roobol MJ, Kranse R, Koning HJ, Schröder FH. Prostate‐specific antigen velocity at low prostate‐specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (Rotterdam). Urology 2004;63(2):309‐13. - PubMed
Roobol 2007 {published data only}
    1. Roobol MJ, Grenabo A, Schröder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2‐ and 4‐year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. Journal of the National Cancer Institute 2007;99:1296‐303. - PubMed
Roobol 2007b {published data only}
    1. Roobol MJ, Zappa M, Maattanen L, Ciatto S. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 2007;67:439‐46. - PubMed
Roobol 2009 {published data only}
    1. Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, et al. Prostate cancer mortality reduction by prostate‐specific antigen‐based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). European Urology 2009;56(4):584‐91. - PubMed
Rosser 2008 {published data only}
    1. Rosser CJ. Prostate cancer ‐ to screen, or not to screen, is that the question?. BMC Urology 2008;8:20. - PMC - PubMed
Scattoni 2008 {published data only}
    1. Scattoni V. Words of wisdom. Re: Is prostate‐specific antigen velocity selective for clinically significant prostate cancer in screening? European randomized study of screening for prostate cancer (Rotterdam). European Urology 2008;54:945‐6. - PubMed
Schröder 1995 {published data only}
    1. Schröder FH, Denis LJ, Kirkels W, Koning HJ, Standaert B. European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies. Cancer 1995;76(1):129‐34. - PubMed
Schröder 1996 {published data only}
    1. Schröder FH, Damhuis RAM, Kirkels WJ, Koning HJ, Kranse R, Nus HGT, et al. European Randomized Study of Screening for Prostate Cancer ‐ the Rotterdam pilot studies. International Journal of Cancer 1996;65(2):145‐51. - PubMed
Schröder 1997 {published data only}
    1. Schröder FH, Bangma CH. The European Randomized Study of Screening for Prostate Cancer (ERSPC). British Journal of Urology 1997;1:68‐71. - PubMed
Schröder 1998 {published data only}
    1. Schröder FH, Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Journal of the National Cancer Institute 1998;90(23):1817‐23. - PubMed
Schröder 1999 {published data only}
    1. Schröder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. European Urology 1999;35(5‐6):539‐43. - PubMed
Schröder 2000 {published data only}
    1. Schröder FH, Cruijsen‐Koeter I, Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. The Journal of Urology 2000;163(3):806‐12. - PubMed
Schröder 2001a {published data only}
    1. Schröder FH, Roobol‐Bouts M, Vis AN, Kwast T, Kranse R. Prostate‐specific antigen‐based early detection of prostate cancer ‐ validation of screening without rectal examination. Urology 2001;57(1):83‐90. - PubMed
Schröder 2001b {published data only}
    1. Schröder FH, Wildhagen MF, Rotterdam Study Group of the 'European Randomised Study of Screening for Prostate Cancer' (ERSPC). Screening for prostate cancer: evidence and perspectives. BJU International 2001;88(8):811‐7. - PubMed
Schröder 2005a {published data only}
    1. Schröder F, Raaijmakers R, Postma R, Kwast T, Roobol M. 4 year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. The Journal of Urology 2005;174:489‐94. - PubMed
Schröder 2008 {published data only}
    1. Schröder F. Screening for prostate cancer (PC) ‐ an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urologic Oncology 2008;26:533‐41. - PubMed
Schröder 2008b {published data only}
    1. Schröder FH, Bangma CH, Roobol MJ. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome‐related information from ERSPC. European Urology 2008;53:901‐8. - PubMed
Schröder 2009 {published data only}
    1. Schröder FH. Review of diagnostic markers for prostate cancer. Recent Results in Cancer Research 2009;181:173‐82. - PubMed
Schröder 2009b {published data only}
    1. Schröder FH, Roobol MJ, Andriole GL, Fleshner N. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. The Journal of Urology 2009;181:69‐74. - PubMed
Shteynshlyuger 2011 {published data only}
    1. Shteynshlyuger A, Andriole GL. Cost‐effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. The Journal of Urology 2011;185(3):828‐32. - PubMed
Sieverding 2008 {published data only}
    1. Sieverding M, Matterne U, Ciccarello L, Luboldt HJ. Early detection of prostate cancer in Germany. A study of a representative random sample of the population. Der Urologe 2008;47:1233‐8. - PubMed
Sotelo 2007 {published data only}
    1. Sotelo RJ, Mora KE, Perez LH, Novoa J, Carmona O, Andrade R, et al. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate‐specific antigen. Urology 2007;69:1143‐6. - PubMed
Stamatiou 2008 {published data only}
    1. Stamatiou K, Skolarikos A, Heretis I, Papadimitriou V, Alevizos A, Ilias G, et al. Does educational printed material manage to change compliance with prostate cancer screening?. World Journal of Urology 2008;26:365‐73. - PubMed
Standaert 1997 {published data only}
    1. Standaert B, Denis L. The European Randomized Study of Screening for Prostate Cancer: an update. Cancer 1997;80(9):1830‐4. - PubMed
Stephens 2008 {published data only}
    1. Stephens RL, Xu Y, Volk RJ, Scholl LE, Kamin SL, Holden EW, et al. Influence of a patient decision aid on decisional conflict related to PSA testing: a structural equation model. Health Psychology 2008;27:711‐21. - PubMed
Steyerberg 2007 {published data only}
    1. Steyerberg EW, Roobol MJ, Kattan MW, Kwast TH, Koning HJ, Schröder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. The Journal of Urology 2007;177:107‐12. - PubMed
Taha 2005 {published data only}
    1. Taha S, Kamal B. Screening program for prostate cancer at a university hospital in eastern Saudi Arabia. Saudi Medical Journal 2005;26:1104‐6. - PubMed
Tarhan 2007 {published data only}
    1. Tarhan F, Orcun A, Kucukercan I, Camursoy N, Kuyumcuoglu U. Effect of hemodialysis on serum complexed prostate‐specific antigen levels. Scandinavian Journal of Urology and Nephrology 2007;41:382‐6. - PubMed
Thompson 2007 {published data only}
    1. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. The Journal of Urology 2007;177:1749‐52. - PubMed
Thompson 2008 {published data only}
    1. Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia MS, Goodman P, et al. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. The Journal of Urology 2008;180:544‐7. - PubMed
Thompson 2008b {published data only}
    1. Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman CA Jr. Does the level of prostate cancer risk affect cancer prevention with finasteride?. Urology 2008;71:854‐7. - PMC - PubMed
Tornblom 2001 {published data only}
    1. Tornblom M, Norming U, Becker C, Lilja H, Gustafsson O. Variation in percentage‐free prostate‐specific antigen (PSA) with prostate volume, age and total PSA level. BJU International 2001;87(7):638‐42. - PubMed
Tornblom 2004 {published data only}
    1. Tornblom M, Eriksson H, Franzen S, Gustafsson O, Lilja H, Norming U, et al. Lead time associated with screening for prostate cancer. International Journal of Cancer 2004;108(1):122‐9. - PubMed
Torres Zambrano 2007 {published data only}
    1. Torres Zambrano G, Lujan Galán M, Pascual Mateo C, García Tello A, Rodríguez N, Berenguer Sánchez A. Preliminary data of the Spanish contribution to the European Randomized Study on Screening of Prostate Cancer (ERSPC) [Datos preliminares de la contribución Española al Estudio Randomizado Europeo de Screening del Cáncer de Próstata (ERSPC)]. Archivos Españoles de Urología 2007;60(7):737‐43. - PubMed
USPSTF 2008 {published data only}
    1. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2008;149(3):185‐91. - PubMed
van den Bergh 2008 {published data only}
    1. Bergh RC, Roobol MJ, Wolters T, Leeuwen PJ, Schröder FH. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU International 2008;102:1068‐73. - PubMed
van Leeuwen 2012 {published data only}
    1. Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, et al. Towards an optimal interval for prostate cancer screening. European Urology 2012;61(1):171‐6. - PubMed
van Weerden 2008 {published data only}
    1. Weerden WM, Schröder FH. The use of PSA as biomarker in nutritional intervention studies of prostate cancer. Chemico‐Biological Interactions 2008;171:204‐11. - PubMed
Varenhorst 1989 {published data only}
    1. Varenhorst E, Enlund AL, Herder A, Malmquist E, Berglund K, Löfman O, et al. Prostatic cancer screening by rectal palpation can be organized with consideration to cost effectiveness. Läkartidningen 1989;86(41):3475‐7. - PubMed
Varenhorst 1991 {published data only}
    1. Varenhorst E, Pedersen KV, Carlsson P, Berglund K, Löfman O. Screening for carcinoma of the prostate in a randomly selected population using duplicate digital rectal examination. Acta Oncologica 1991;30(2):273‐5. - PubMed
Verratti 2007 {published data only}
    1. Verratti V, Giulio C, Francesco S, Berardinelli F, Pellicciotta M, Gidaro S, et al. Chronic hypoxia, physical exercise and PSA: correlation during high‐altitude trekking (2004 K2 expedition). Urologia Internationalis 2007;78:305‐7. - PubMed
Vickers 2008 {published data only}
    1. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Medicine 2008;6:19. - PMC - PubMed
Villers 2008 {published data only}
    1. Villers A. Practical follow‐up of a patient treated with finasteride in screening for prostate cancer [Suivi pratique d’un patient traité par finastéride pour le dépistage de cancer de prostate]. Progrès en Urologie 2008;18 Suppl 3:S58‐62. - PubMed
Vis 2001a {published data only}
    1. Vis AN, Hoedemaeker RF, Kwast TH, Schröder FH. Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model. Prostate 2001;46(2):154‐62. - PubMed
Vis 2001b {published data only}
    1. Vis AN, Hoedemaeker RF, Roobol M, Kwast TH, Schröder FH. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0‐3.9 ng/ml). Prostate 2001;47(4):252‐61. - PubMed
Vis 2002 {published data only}
    1. Vis AN, Kranse R, Roobol M, Kwast TH, Schröder FH. Serendipity in detecting disease in low prostate‐specific antigen ranges. BJU International 2002;89(4):384‐9. - PubMed
Vis 2007 {published data only}
    1. Vis AN, Roemeling S, Kranse R, Schröder FH, Kwast TH. Should we replace the Gleason score with the amount of high‐grade prostate cancer?. European Urology 2007;51:931‐9. - PubMed
Wallner 2008 {published data only}
    1. Wallner LP, Sarma AV, Lieber MM, Sauver JL, Jacobson DJ, McGree ME, et al. Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: the Olmsted County study. Cancer Epidemiology, Biomarkers & Prevention 2008;17:3588‐92. - PMC - PubMed
Weinrich 2007 {published data only}
    1. Weinrich SP, Seger R, Curtsinger T, Pumphrey G, NeSmith EG, Weinrich MC. Impact of pretest on posttest knowledge scores with a Solomon Four research design. Cancer Nursing 2007;30:E16‐28. - PubMed
Weiss 2008 {published data only}
    1. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. International Journal of Cancer 2008;122:2345‐50. - PubMed
Wilbur 2008 {published data only}
    1. Wilbur J. Prostate cancer screening: the continuing controversy. American Family Physician 2008;78:1377‐84. - PubMed
Wilt 2008 {published data only}
    1. Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. 5‐alpha‐reductase inhibitors for prostate cancer prevention. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD007091] - DOI - PMC - PubMed
Wolters 2008 {published data only}
    1. Wolters T, Roobol MJ, Schröder FH, Kwast TH, Roemeling S, Cruijsen‐Koeter IW, et al. Can non‐malignant biopsy features identify men at increased risk of biopsy‐detectable prostate cancer at re‐screening after 4 years?. BJU International 2008;101:283‐8. - PubMed
Wolters 2010 {published data only}
    1. Wolters T, Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH, et al. False‐negative prostate needle biopsies: frequency, histopathologic features, and follow‐up. The American Journal of Surgical Pathology 2010;34(1):35‐43. - PubMed
Yang 2008 {published data only}
    1. Yang Y. Treatment of the positive surgical margin following radical prostatectomy. Chinese Medical Journal 2008;121(4):375‐9. - PubMed
Yasunaga 2008 {published data only}
    1. Yasunaga H. Willingness to pay for mass screening for prostate cancer: a contingent valuation survey. International Journal of Urology 2008;15:102‐5. - PubMed
Zackrisson 2003 {published data only}
    1. Zackrisson B, Aus G, Lilja H, Lodding P, Pihl CG, Hugosson J. Follow‐up of men with elevated prostate‐specific antigen and one set of benign biopsies at prostate cancer screening. European Urology 2003;43(4):327‐32. - PubMed
Zackrisson 2004 {published data only}
    1. Zackrisson B, Aus G, Bergdahl S, Lilja H, Lodding P, Pihl CG, et al. The risk of finding focal cancer (less than 3 mm) remains high on re‐biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. The Journal of Urology 2004;171(4):1500‐3. - PubMed
Zhu 2011 {published data only}
    1. Zhu X, Leeuwen PJ, Bul M, Otto SJ, Koning HJ, Bangma CH, et al. Disease‐specific survival of men with prostate cancer detected during the screening interval: results of the European Randomized Study of Screening for Prostate Cancer ‐ Rotterdam after 11 years of follow‐up. European Urology 2011;60(2):330‐6. - PubMed

References to ongoing studies

CAP {published data only}
    1. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. European Journal of Cancer 2010;46(17):3095‐101. - PubMed
    1. Pashayan N, Duffy SW, Pharoah P, Greenberg D, Donovan J, Martin RM, et al. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. British Journal of Cancer 2009;100:1198‐204. - PMC - PubMed

Additional references

ACS 2010
    1. Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer (update 2010). CA: A Cancer Journal for Clinicians 2010;60(2):70‐98. - PubMed
AUA 2009
    1. American Urological Association. Prostate‐specific antigen best practice statement: 2009 update. American Urological Association Education and Research, Inc.; 2009; http://www.auanet.org/content/media/psa09.pdf?CFID=1939643&CFTOKEN=6... (accessed 12/05/2010).
Bartsch 2001
    1. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, et al. Prostate cancer mortality after introduction of prostate‐specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001;58:417‐24. - PubMed
Berry 1984
    1. Berry S, Coffey D, Walsh P, Ewing L. The development of human benign prostatic hyperplasia with age. The Journal of Urology 1984;132:474‐9. - PubMed
Bill‐Axelson 2005
    1. Bill‐Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. The New England Journal of Medicine 2005;352:1977‐84. - PubMed
Bill‐Axelson 2008
    1. Bill‐Axelson A, Holmber L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group‐4 Randomized Trial. Journal of the National Cancer Institute 2008;100:1144‐54. - PMC - PubMed
Bill‐Axelson 2011
    1. Bill‐Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. The New England Journal of Medicine 2011;364:1708‐17. - PubMed
Burford 2010
    1. Burford DC, Kirby M, Austoker J. Prostate Cancer Risk Management Programme information for primary care; PSA testing in asymptomatic men. Evidence document. NHS Cancer Screening Programmes; 2010 Jan.; http://www.cancerscreening.nhs.uk/prostate/pcrmp‐guide‐2.html (accessed 12/05/2010).
de Koning 2002b
    1. Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. International Journal of Cancer 2002;98(2):268‐73. - PubMed
de Koning 2003
    1. Koning HJ, Hakulinen T, Moss SM, Adolfsson J, Smith PH, Alexanders FE, et al. Monitoring the ERSPC trial. BJU International 2003;92 Suppl 2:112‐4. - PubMed
Djulbegovic 2010
    1. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta‐analysis of randomised controlled trials. BMJ 2010;341:c4543. - PMC - PubMed
Draisma 2003
    1. Draisma G, Boer R, Otto SJ, Cruijsen IW, Damhuis RAM, Schröder F, et al. Lead time and over detection due to prostate‐specific antigen screening: Estimates from the European Rondomized Study of Screening for Prostate Cancer. Journal of the National Cancer Institute 2003;95(12):868‐78. - PubMed
EAU 2012
    1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on prostate cancer. European Association of Urology; 2012 Feb.; http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%2... (accessed 1 November 2012).
Gambert 2001
    1. Gambert SR. Screening for prostate cancer. International Urology and Nephrology 2001;33(2):249‐57. - PubMed
Grönberg 2003
    1. Grönberg P. Prostate cancer epidemiology. Lancet 2003;361(9360):859‐64. - PubMed
Guyatt 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. - PubMed
Hamashima 2009
    1. Hamashima C, Nakayama T, Sagawa M, Saito H, Sobue T. The Japanese guideline for prostate cancer screening. Japanese Journal of Clinical Oncology 2009;39(6):339‐51. - PubMed
Heidenreich 2011
    1. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European Urology 2011;59(1):61‐71. - PubMed
Heijnsdijk 2012
    1. Heijnsdijk EAM, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality‐of‐life effects of prostate‐specific antigen screening. The New England Journal of Medicine 2012;367(7):595‐605. - PMC - PubMed
Higgins 2005
    1. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd, updated May 2005.
Higgins 2011
    1. Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2011.
Holman 1999
    1. Holman C, Wisniewski Z, Semmens J, Rouse I, Bass A. Mortality and prostate cancer risk in 19598 men after surgery for benign prostatic hyperplasia. BJU International 1999;84:37‐42. - PubMed
Holmström 2009
    1. Holmström B, Johansson M, Bergh A, Stenman U‐H, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 2009;339:b3537. - PMC - PubMed
Howlader 2012
    1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER Cancer Statistics Review, 1975‐2009 (Vintage 2009 Populations), National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/index.html (accessed 15 November 2012).
Jacobsen 1998
    1. Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, et al. Screening digital rectal examination and prostate cancer mortality: a population‐based case‐control study. Urology 1998;52:173‐9. - PubMed
Jemel 2011
    1. Jemel A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer Journal for Clinicians 2011;61:69‐90. - PubMed
Johansson 2009
    1. Johansson E, Bill‐Axelson A, Holmberg L, Onelov E, Johansson J, Steineck G. Time, symptom burden, androgen deprivation, and self‐assessed quality of life after radical prostatectomy or watchful waiting: The randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG‐4) clinical trial. European Urology 2009;55:422‐32. - PubMed
Jones 2010
    1. Jones C, Hill J, Chappele C. Management of lower urinary tract symptoms in men: summary of NICE guidance. BMJ 2010;340:c2354. - PubMed
JUA 2010
    1. The Committee for Establishment of the Guidelines on Screening for Prostate Cancer, Japanese Urological Association. Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010. International Journal of Urology 2010;17(10):830‐8. - PubMed
Kopec 2005
    1. Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, et al. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case‐control study. The Journal of Urology 2005;174:495‐9. - PubMed
Lu‐Yao 2009
    1. Lu‐Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009;302(11):1202‐9. - PMC - PubMed
Lumen 2012
    1. Lumen N, Fonteyne V, Meerleert G, Ost P, Villeirs G, Mottrie A, et al. Population screening for prostate cancer: An overview of available studies and meta‐analysis. International Journal of Urology 2012;19(2):100‐8. - PubMed
O'Connor 2009
    1. O’Connor A, Bennett C, Stacey D, Barry M, Col N, Eden K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001431.pub2] - DOI - PubMed
Parkin 2005
    1. Parkin M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005;55(2):74‐108. - PubMed
Partin 1993
    1. Partin A, Yoo J, Carter H, Pearson J, Chan D, Epstein J, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. The Journal of Urology 1993;150:110‐4. - PubMed
Raaijmakers 2002
    1. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schröder FH. Complication rates and risk factors of 5802 transrectal ultrasound‐guided sextant biopsies of the prostate within a population‐based screening program. Urology 2002;60(5):826‐30. - PubMed
RACGP 2012
    1. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice, 8th edition. East Melbourne: The Royal Australian College of General Practitioners; 2012; http://www.racgp.org.au/your‐practice/guidelines/redbook/ (accessed 1 November 2012).
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Rosario 2012
    1. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 2012;344:d7894. - PMC - PubMed
Sakr 1996
    1. Sakr W, Grignon D, Haas G, Heilbrum L, Pontes J, Crissman J. Age and racial distribution of prostatic intraepithelial neoplasia. European Urology 1996;30:138‐44. - PubMed
Schröder 2003
    1. Schröder FH, Denis LJ, Roobol M, all participants of the ERSPC. The story of the European Randomized Study of Screening for Prostate Cancer. BJU International 2003;92 Suppl 2:1‐13. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Sterne 2001
    1. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. BMJ 2001;323:101‐5. - PMC - PubMed
USPSTF 2012
    1. Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2012;157(2):120‐34. - PubMed
van Leeuwen 2010
    1. Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. European Journal of Cancer 2010;46:377‐83. - PubMed
WHO 1968
    1. Wilson J, Jungner G. Principles and practice of screening for disease. World Health Organization 1968.
Wilt 2008a
    1. Wilt T, MacDonald R, Rutks I, Shamliyan T, Taylor B, Kane R. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Annals of Internal Medicine 2008;148:435‐48. - PubMed
Wilt 2012
    1. Wilt T, Brawer M, Jones K, Barry M, Aronson W, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. The New England Journal of Medicine 2012;367:203‐13. - PMC - PubMed

References to other published versions of this review

Ilic 2006
    1. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004720.pub2] - DOI - PubMed
Ilic 2010
    1. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD004720.pub2] - DOI - PubMed

Publication types

MeSH terms

Substances